Investors should monitor upcoming data presentations at the MDA Conference (March 8–11, 2026) and the Q2 2026 BLA submission for z-rostudirsen as key catalysts. The strong cash runway reduces near-term dilution risk despite high burn.
DYN drugs
DYN drug pipeline →- ▲ z-rostudirsen 8/10 Filed (BLA under FDA Priority Review); Phase 3 confirmatory trial (FORZETTO) ongoing · PDUFA date Jan 21, 2027
- ◆ z-basivarsen 7/10 Phase 3 (HARMONIA confirmatory trial, initiated March 2026); Phase 1/2 registrational cohort (ACHIEVE) fully enrolled · BLA filing Q3 2027
- ● DYNE-302 2/10
- All DYN drugs, catalysts & trials →
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 2 $16.15entry
- T+1 · 9mo ago −9.60%α −8.68% · $14.60
- T+5 · 8mo ago +9.54%α +10.74% · $17.69
- T+20 · 8mo ago +5.82%α +13.76% · $17.09
- T+60 · 6mo ago +12.38%α +3.06% · $18.15
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Dyne Therapeutics reported positive topline results from the Phase 1/2 DELIVER trial of z-rostudirsen in Duchenne muscular dystrophy, showing statistically significant dystrophin expression and functional improvements. The company plans a Q2 2026 BLA submission for accelerated approval, with a potential U.S. launch in Q1 2027. Cash remains strong at $1.1 billion, supporting operations into Q1 2028, despite increased R&D and net losses.
Key Financial Metrics
Key Facts
- Positive topline results from DELIVER trial: 5.46% normal dystrophin expression at 6 months (7-fold increase, p<0.0001); functional improvements in TTR and 10MWR vs. placebo (nominal p<0.05).
- Z-rostudirsen safety profile remains favorable, with mostly mild-to-moderate treatment-related adverse events.
- BLA submission for z-rostudirsen planned for Q2 2026; potential U.S. launch in Q1 2027 assuming Priority Review.
- Enrollment in ACHIEVE trial for z-basivarsen in DM1 on track for completion in Q2 2026, with BLA submission expected in early Q3 2027.
- Cash, cash equivalents, and marketable securities totaled $1.11 billion as of December 31, 2025, sufficient to fund operations into Q1 2028.
- R&D expenses increased to $398.3 million in 2025 from $281.4 million in 2024; net loss widened to $446.2 million in 2025 from $317.4 million in 2024.
Financial Impact
Increased R&D spend of $116.9 million YoY and net loss expansion of $128.8 million reflect advancing clinical programs, offset by strong cash position of $1.11 billion.
Risk Factors
- Clinical trial results are not powered for statistical significance on functional endpoints; confirmatory Phase 3 trials are required.
- Regulatory approval is not guaranteed, even with accelerated pathway plans.
- Increased operating losses may pressure valuation if clinical milestones are delayed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3247269 |
Track record
54 reports on DYN
11 of 15 bullish or bearish reports moved the stock their way by T+20. Best: +46.36% at T+60 after the May 20, 2026 report. 14 of 15 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $16.77 Now $16.70 −0.39% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $17.36 Now $16.70 −3.80% settles Dec 4
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $17.04 Now $16.70 −2.00% settles Nov 27
- Oct 22, 202625d ago Press Release Neutral 2/10 Entry $15.62 Now $16.70 +6.91% settles Nov 20
- Oct 12, 20265w ago Institutional Cluster Mixed 4/10 Entry $15.96 to $18.62 Now $16.70 +4.64% ▲ +16.67% +19.93% vs SPY
- Sep 29, 20266w ago Press Release Bullish 7/10 Entry $16.11 to $16.94 Now $16.70 +3.66% ▲ +5.15% +4.23% vs SPY
- Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $19.19 to $15.97 Now $16.70 −12.98% ▼ −16.78% −18.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers